Skip to main content
BayerEarnings

Bayer revises its 2026 profit forecasts upwards following excellent results from its pharmaceutical division

Source: Autobound Signal API · 70 signals tracked for Bayer · updated

Get Bayer's live signals in Claude or ChatGPT, or by API

AskWhat changed at Bayer this week? Use Autobound signals for bayer.com.

What happened

Bayer reported third-quarter adjusted EBITDA of 1.62 billion euros, exceeding market forecasts by roughly 13 percent.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Following a better-than-expected third quarter in its pharmaceutical division, German group Bayer has revised its 2026 profit forecasts upwards. The company now expects its core profit, adjusted for exchange rate effects, to total between 9.8 and 10.3 billion euros for the full year. This represents an increase from previous forecasts, which ranged between 9.6 and 10.1 billion euros. The pharmaceutical division posted strong results, with quarterly revenue of 4.68 billion euros. This figure is 5 percent higher than analysts' forecasts. The company's adjusted EBITDA for the third quarter also exceeded market expectations, coming in at 1.62 billion euros, or about 13 percent higher than anticipated. CEO Bill Anderson stated that the pharmaceutical division is entering a new phase of growth. Financially, the group is working to pay down the massive debt incurred during the 56.2 billion euro acquisition of Monsanto in 2018, a deal that also resulted in costly legal disputes regarding the Roundup herbicide. Bayer has revised its year-end net debt forecast downward by 1 billion euros, now expecting it to be around 29 billion euros. Regarding the legal disputes, Bill Anderson stated that a 6.47 billion euro settlement aimed at resolving Roundup-related lawsuits is expected to be finalized before the end of the year, though this agreement still requires court approval. This...

Keep reading with a free account

The rest of this article, and every signal for Bayer, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Earnings

What this signalsEarnings results often set the next budget cycle.

Location
Germany

The full record

From the Signal API record

Extraction

Confidence
95%
Detected
Nov 3, 2026
signal_type
news
signal_subtype
has_earnings

Use this data

Get every earnings signal for Bayer and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Bayer this week?”

  2. Send it to your own tools

    The Signal API returns earnings signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/0a77cc6d-8e72-6b58-7d20-ddbeb1f2d316 returns this record as JSON. POST /v1/companies/enrich returns every signal for bayer.com.

{
  "signal_id": "0a77cc6d-8e72-6b58-7d20-ddbeb1f2d316",
  "signal_type": "news",
  "signal_subtype": "has_earnings",
  "detected_at": "2026-11-03T18:44:00+00:00",
  "company": {
    "name": "Bayer",
    "domain": "bayer.com"
  },
  "data": {
    "url": "https://fr.businessam.be/bayer-revoit-a-la-hausse-ses-previsions-de-benefices-pour-2026-grace-a-la-croissance-de-sa-division-pharmaceutique/",
    "title": "Bayer revises its 2026 profit forecasts upwards following excellent results from its pharmaceutical division - Business AM",
    "excerpt": "Following a better-than-expected third quarter in its pharmaceutical division, German group Bayer has revised its 2026 profit forecasts upwards. The company now expects its core profit, adjusted for exchange rate effects, to total between 9.8 and 10.3 billion euros for the full year. This represents an increase from previous forecasts, which ranged between 9.6 and 10.1 billion euros. The pharmaceutical division posted strong results, with quarterly revenue of 4.68 billion euros. This figure is 5 percent higher than analysts' forecasts. The company's adjusted EBITDA for the third quarter also exceeded market expectations, coming in at 1.62 billion euros, or about 13 percent higher than anticipated. CEO Bill Anderson stated that the pharmaceutical division is entering a new phase of growth. Financially, the group is working to pay down the massive debt incurred during the 56.2 billion euro acquisition of Monsanto in 2018, a deal that also resulted in costly legal disputes regarding the Roundup herbicide. Bayer has revised its year-end net debt forecast downward by 1 billion euros, now expecting it to be around 29 billion euros. Regarding the legal disputes, Bill Anderson stated that a 6.47 billion euro settlement aimed at resolving Roundup-related lawsuits is expected to be finalized before the end of the year, though this agreement still requires court approval. This settlement...",
    "summary": "Bayer reported third-quarter adjusted EBITDA of 1.62 billion euros, exceeding market forecasts by roughly 13 percent.",
    "location": "Germany",
    "planning": false,
    "image_url": "https://media.businessam.be/h_3.71848912-1.jpg",
    "confidence": 0.95,
    "published_at": "2026-11-03T18:44:00Z",
    "location_data": [
      {
        "region": "Western Europe",
        "country": "Germany",
        "continent": "Europe",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "The company's adjusted EBITDA for the third quarter also exceeded market expectations, coming in at 1.62 billion euros, or about 13 percent higher than anticipated."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.